{
    "pmcid": "10302031",
    "qa_pairs": {
        "What is a key advantage of nanobodies derived from camelids in targeting SARS-CoV-2?": [
            "Their small size allows them to access conserved regions less accessible to traditional antibodies.",
            "They can directly neutralize the virus without binding to any epitopes.",
            "They are naturally resistant to all SARS-CoV-2 mutations.",
            "They can only bind to the S2 subunit of the spike protein."
        ],
        "What is one potential therapeutic strategy mentioned for preventing SARS-CoV-2 entry into host cells?": [
            "Targeting the ACE2 receptor with mAbs",
            "Inhibiting the N-terminal domain (NTD)",
            "Blocking the S2 subunit",
            "Targeting the glycan shield"
        ],
        "What is the primary target for neutralizing antibodies in the SARS-CoV-2 spike protein?": [
            "The receptor-binding domain (RBD)",
            "The N-terminal domain (NTD)",
            "The S2 subunit",
            "The glycan shield"
        ],
        "Which novel approach combines a non-neutralizing antibody with an ACE2 domain for broad-spectrum neutralization?": [
            "ReconnAbs",
            "Multivalent nanobodies",
            "Bispecific antibodies",
            "Combination therapies"
        ],
        "Why have many clinically authorized monoclonal antibodies become ineffective against the Omicron variant?": [
            "Significant mutations in the RBD have altered binding surfaces for ACE2 and antibodies.",
            "The Omicron variant has a completely different spike protein structure.",
            "The Omicron variant does not use ACE2 as a receptor for entry.",
            "The Omicron variant has developed resistance to all forms of antibodies."
        ]
    }
}